Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Senate panel bars prior authorization for most medication‑assisted opioid treatment
Summary
HB 16‑56 removes prior‑authorization requirements for many pill‑ and film‑based medication‑assisted treatments (buprenorphine formulations), while preserving prior authorization for injectable treatments; the committee adopted an amendment to address Medicaid rebate concerns and gave Medicaid until January to comply.
The Senate Insurance & Commerce Committee passed House Bill 16‑56, a measure designed to reduce barriers to medication‑assisted treatment (MAT) for opioid dependence by restricting insurers and Medicaid from requiring prior authorization for certain MAT prescriptions.
Representative Ferguson, the sponsor, said the bill aims to make it easier and faster for patients to start treatment. She cited House testimony…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
